Omega Healthcare Invts (NYSE:OHI) Stock

Omega Healthcare Invts

Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).

Skyscrapers,Cityscape,Downtown,View,,Nashville,Skyline,Buildings.,Beautiful,Real,Estate.

News

Dividends

Price Target

Markets

Analyst Ratings

Trading Ideas

Wall Street&#39;s Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields

Concept,Of,Business,Prosperity,And,Asset,Management,,Real,Estate,Investment

Pre-Market Outlook

Wall Street&#39;s Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields

8 Best Dividend Challengers Stocks To Buy In September 2024

Wall Street&#39;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields

Omega Healthcare Investors, Inc. Common Stock

Omega Healthcare Investors Inc

OHIO ART CO by Ohio Art Company (The)

Ohio Valley Banc Corporation

<p>JMP Securities  analyst Aaron Hecht   reiterates Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) from Market Perform to Market Perform.</p>


Reiteration

JMP Securities Reiterates Market Perform on Omega Healthcare Invtsto Market Perform

<p>The earnings results for <strong>Omega Healthcare Invts</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) for Q4 were made public on Wednesday, February 5, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Omega Healthcare Invts beat estimated earnings by 1.0%, reporting an EPS of $0.74 versus an estimate of $0.73.</p>
<p>Revenue was up $40.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous quarter, the company beat on EPS by $0.03, resulting in a 0.0% increase change in the share price the following day.</p>
<p>Here's a look at Omega Healthcare Invts's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.71</td>
<td>0.68</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.74</td>
<td>0.71</td>
<td>0.68</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>261.64M</td>
<td>246.73M</td>
<td>231.64M</td>
<td>233.82M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>276.03M</td>
<td>252.75M</td>
<td>243.30M</td>
<td>239.32M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Omega Healthcare Invts management provided guidance for FY 2025, expecting earnings between $2.9 and $2.98 per share.</p>
<p>To track all earnings releases for Omega Healthcare Invts <a href="https://www.benzinga.com/quote/OHI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

Omega Healthcare Invts Q4 Earnings Assessment

<p><strong>Omega Healthcare Invts</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) reported its Q4 earnings results on Wednesday, February 5, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Omega Healthcare Invts beat estimated earnings by 1.0%, reporting an EPS of $0.74 versus an estimate of $0.73.</p>
<p>Revenue was up $40.00 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.03 in the previous quarter, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Omega Healthcare Invts's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.71</td>
<td>0.68</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.74</td>
<td>0.71</td>
<td>0.68</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>261.64M</td>
<td>246.73M</td>
<td>231.64M</td>
<td>233.82M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>276.03M</td>
<td>252.75M</td>
<td>243.30M</td>
<td>239.32M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Omega Healthcare Invts management provided guidance for FY 2025, expecting earnings between $2.9 and $2.98 per share.</p>
<p>To track all earnings releases for Omega Healthcare Invts <a href="https://www.benzinga.com/quote/OHI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Breakdown: Omega Healthcare Invts Q4

<p>The Q4 earnings report for <strong>Omega Healthcare Invts</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) was released on Wednesday, February 5, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Omega Healthcare Invts beat estimated earnings by 1.0%, reporting an EPS of $0.74 versus an estimate of $0.73.</p>
<p>Revenue was up $40.00 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>During the previous quarter, the company beat on EPS by $0.03, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Omega Healthcare Invts's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.71</td>
<td>0.68</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.74</td>
<td>0.71</td>
<td>0.68</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>261.64M</td>
<td>246.73M</td>
<td>231.64M</td>
<td>233.82M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>276.03M</td>
<td>252.75M</td>
<td>243.30M</td>
<td>239.32M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Omega Healthcare Invts management provided guidance for FY 2025, expecting earnings between $2.9 and $2.98 per share.</p>
<p>To track all earnings releases for Omega Healthcare Invts <a href="https://www.benzinga.com/quote/OHI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Omega Healthcare Invts: Q4 Earnings Insights

<p><strong>Omega Healthcare Invts</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) reported its Q4 earnings results on Wednesday, February 5, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Omega Healthcare Invts beat estimated earnings by 1.0%, reporting an EPS of $0.74 versus an estimate of $0.73.</p>
<p>Revenue was up $40.00 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>During the previous quarter, the company beat on EPS by $0.03, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Omega Healthcare Invts's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.71</td>
<td>0.68</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.74</td>
<td>0.71</td>
<td>0.68</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>261.64M</td>
<td>246.73M</td>
<td>231.64M</td>
<td>233.82M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>276.03M</td>
<td>252.75M</td>
<td>243.30M</td>
<td>239.32M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Omega Healthcare Invts management provided guidance for FY 2025, expecting earnings between $2.9 and $2.98 per share.</p>
<p>To track all earnings releases for Omega Healthcare Invts <a href="https://www.benzinga.com/quote/OHI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Omega Healthcare Invts Q4

<p>The earnings results for <strong>Omega Healthcare Invts</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) for Q4 were made public on Wednesday, February 5, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Omega Healthcare Invts beat estimated earnings by 1.0%, reporting an EPS of $0.74 versus an estimate of $0.73.</p>
<p>Revenue was up $40.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>During the previous quarter, the company beat on EPS by $0.03, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Omega Healthcare Invts's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.71</td>
<td>0.68</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.74</td>
<td>0.71</td>
<td>0.68</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>261.64M</td>
<td>246.73M</td>
<td>231.64M</td>
<td>233.82M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>276.03M</td>
<td>252.75M</td>
<td>243.30M</td>
<td>239.32M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Omega Healthcare Invts management provided guidance for FY 2025, expecting earnings between $2.9 and $2.98 per share.</p>
<p>To track all earnings releases for Omega Healthcare Invts <a href="https://www.benzinga.com/quote/OHI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Omega Healthcare Invts Q4 Earnings Report: What Investors Need to Know

Guidance

Omega Healthcare Investors Sees FY25 Adj. FFO $2.90-$2.98 Vs $2.99 Est.

<p>The Q4 earnings report for <strong>Omega Healthcare Invts</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) was released on Wednesday, February 5, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Omega Healthcare Invts beat estimated earnings by 1.0%, reporting an EPS of $0.74 versus an estimate of $0.73.</p>
<p>Revenue was up $40.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company beat on EPS by $0.03 in the last quarter, resulting in a 0.0% increase share price change the following day.</p>
<p>Here's a look at Omega Healthcare Invts's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.71</td>
<td>0.68</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.74</td>
<td>0.71</td>
<td>0.68</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>261.64M</td>
<td>246.73M</td>
<td>231.64M</td>
<td>233.82M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>276.03M</td>
<td>252.75M</td>
<td>243.30M</td>
<td>239.32M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Omega Healthcare Invts management provided guidance for FY 2025, expecting earnings between $2.9 and $2.98 per share.</p>
<p>To track all earnings releases for Omega Healthcare Invts <a href="https://www.benzinga.com/quote/OHI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Omega Healthcare Invts Earnings Review: Q4 Summary

<p>Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.73 by 1.37 percent. This is a 8.82 percent increase over earnings of $0.68 per share from the same period last year.  The company reported quarterly sales of $279.318 million which beat the analyst consensus estimate of $275.668 million by 1.32 percent.  This is a 16.71 percent increase over sales of $239.319 million the same period last year.</p>


Earnings Beats

Omega Healthcare Invts Q4 2024 FFO $0.74 Beats $0.73 Estimate, Sales $279.318M Beat $275.668M Estimate

ALGN

AMSC

AOSL

APPS

ARAY

ARCC

ARES

ASGN

ASYS

AZTA

BARK

BLBD

BSBR

CENT

CENTA

CMRE

CNMD

CNXN

COHR

CPAY

CPRI

CRTO

CSGS

CTSH

CTVA

DGII

DLHC

ENSG

EQNR

EZPW

FORM

GEOS

HOLX

ITUB

KMPR

LFVN

LSAK

LUCK

LVWR

MSTR

MTRX

MUSA

NOTV

NTGR

NVST

NWSA

ODFL

ORLY

PAHC

PFGC

Earnings Scheduled For February 5, 2025

<p>During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.</p>
<p>Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.</p>
<p>Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.</p>
<h3 class="wp-block-heading"><strong>Medical Properties Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 8.54%</li>
<li><strong>Truist Securities </strong>analyst Michael Lewis maintained a Hold rating and cut the price target from $6 to $4 on Dec. 19, 2024. This analyst has an accuracy rate of 69%.</li>
<li><strong>RBC Capital </strong>analyst Michael Carroll downgraded the stock from Outperform to Sector Perform with a price target of $5 on May 14, 2024. This analyst has an accuracy rate of 61%.</li>
<li><strong>Recent News:</strong> On Nov.7, Medical Properties Trust reported worse-than-expected third-quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1">latest MPW news.</a> </li>
</ul>
<p><figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/8356f98b-748a-4a66-8e7b-6e4f0dc6db31" alt="" style="width:606px;height:auto" /></a></figure></p>
<h3 class="wp-block-heading"><strong>EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 7.74%</li>
<li><strong>JP Morgan </strong>analyst Anthony Paolone maintained an Overweight rating and raised the price target from $48 to $51 on Sept. 9, 2024. This analyst has an accuracy rate of 64%.</li>
<li><strong>Truist Securities </strong>analyst Ki Bin Kim maintained a Hold rating and boosted the price target from $44 to $46 on Aug. 16, 2024. This analyst has an accuracy rate of 67%.</li>
<li><strong>Recent News:</strong> On Oct. 30, EPR Props posted better-than-expected quarterly results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1">latest EPR new</a>s.</li>
</ul>
<p><figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/25fde8ab-3a45-4b71-980a-0efe0c0d9950" alt="" style="width:631px;height:auto" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield: </strong>7.39%</li>
<li><strong>RBC Capital </strong>analyst Michael Carroll maintained a Sector Perform rating and raised the price target from $39 to $43 on Nov. 11, 2024. This analyst has an accuracy rate of 61%.</li>
<li><strong>Wells Fargo </strong>analyst Connor Siversky assumed an Overweight rating and increased the price target from $40 to $43 on Oct. 1, 2024. This analyst has an accuracy rate of 63%.</li>
<li><strong>Recent News: </strong>On Jan. 6, Omega Healthcare Investors named Matthew Gourmand as President.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1">OHI news</a>.</li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="893" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64.png" alt="" class="wp-image-728777" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64.png 893w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64-768x711.png 768w" sizes="(max-width: 893px) 100vw, 893px" /></a></figure></p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/01/42917071/top-2-health-care-stocks-that-are-ticking-portfolio-bombs-2">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a></strong></li>
</ul>


Wall Street's Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields

Management

Omega Healthcare Investors Appoints Matthew Gourmand As President; COO Dan Booth Resigns

<p>During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.</p>
<p>Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.</p>
<p>Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.</p>
<h3 class="wp-block-heading"><strong>Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 7.08%</li>
<li><strong>Wells Fargo </strong>analyst Connor Siversky assumed an Overweight rating and raised the price target from $40 to $43 on Oct. 1. This analyst has an accuracy rate of 65%.</li>
<li><strong>Truist Securities</strong> analyst Michael Lewis maintained a Hold rating and raised the price target from $33 to $39 on Sept. 4. This analyst has an accuracy rate of 71%.</li>
<li><strong>Recent News:</strong> On Oct. 30, Omega Healthcare Investors reported better-than-expected third-quarter financial results and raised its FY24 adjusted FFO guidance.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1">latest OHI news</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="910" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188.png" alt="" class="wp-image-704244" style="width:688px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188-768x709.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>OUTFRONT Media Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUT#NYSE">OUT</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 6.60%</li>
<li><strong>Morgan Stanley </strong>analyst Benjamin Swinburne maintained an Equal-Weight rating and raised the price target from $17 to $18 on Dec. 18. This analyst has an accuracy rate of 76%.</li>
<li><strong>Barrington Research </strong>analyst James Goss maintained an Outperform rating with a price target of $21 on Nov. 13. This analyst has an accuracy rate of 62%.</li>
<li><strong>Recent News: </strong>On Nov. 12, Outfront Media posted mixed quarterly results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1">latest OUT news</a> </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="892" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189.png" alt="" class="wp-image-704245" style="width:575px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189.png 892w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189-768x717.png 768w" sizes="(max-width: 892px) 100vw, 892px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>LTC Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTC#NYSE">LTC</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield: </strong>6.50%</li>
<li><strong>Wells Fargo </strong>analyst Connor Siversky assumed an Equal-Weight rating and raised the price target from $36 to $37 on Oct. 1. This analyst has an accuracy rate of 65%.</li>
<li><strong>Wedbush </strong>analyst Richard Anderson reiterated an Outperform rating and a price target of $40 on Sept. 20. This analyst has an accuracy rate of 65%.</li>
<li><strong>Recent News: </strong>LTC named Wendy Simpson Executive Chairman Of The Board, promoted Pam Kessler and Clint Malin to co-Chief Executive Officers, and Cece Chikhale Tto Chief Financial Officer, effective Dec. 31.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"> trend in LTC stock</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="898" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190.png" alt="" class="wp-image-704248" style="width:623px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190.png 898w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190-768x716.png 768w" sizes="(max-width: 898px) 100vw, 898px" /></a></figure></p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></strong></li>
</ul>


Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields

<p>BMO Capital  analyst Juan Sanabria   upgrades Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) from Market Perform to Outperform and maintains the price target from $45 to $45.</p>


Upgrades

BMO Capital Upgrades Omega Healthcare Invts to Outperform, Maintains Price Target to $45

<p>In the latest quarter, 5 analysts provided ratings for Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.6, a high estimate of $45.00, and a low estimate of $37.00. This current average has increased by 7.85% from the previous average price target of $39.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733410821_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Omega Healthcare Invts. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$43.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Kai Klose</td>
<td>Berenberg</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Juan Sanabria</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Omega Healthcare Invts. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Omega Healthcare Invts compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Omega Healthcare Invts's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Omega Healthcare Invts's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OHI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Omega Healthcare Invts analyst ratings.</strong></a></p>
<h2>Get to Know Omega Healthcare Invts Better</h2>
<p>Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).</p>
<h3>Financial Insights: Omega Healthcare Invts</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Omega Healthcare Invts's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>14.05%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.</p>
<p><strong>Net Margin:</strong> Omega Healthcare Invts's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>40.49%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Omega Healthcare Invts's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>2.82%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Omega Healthcare Invts's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.21%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Omega Healthcare Invts's debt-to-equity ratio is below the industry average at <strong>1.15</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


5 Analysts Assess Omega Healthcare Invts: What You Need To Know

<p>Mizuho  analyst Haendel St. Juste   maintains Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Neutral and raises the price target from $35 to $37.</p>


Mizuho Maintains Neutral on Omega Healthcare Invts, Raises Price Target to $37

<p>In the current market session, <strong>Omega Healthcare Invts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</strong> stock price is at $40.93, after a <strong>1.10%</strong> drop. However, over the past month, the company's stock spiked by <strong>1.67%</strong>, and in the past year, by <strong>31.23%</strong>. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1731431745_0.png" alt="Past Year Chart" /></p>

<h3>A Look at Omega Healthcare Invts P/E Relative to Its Competitors</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Compared to the aggregate P/E ratio of the <strong>45.15</strong> in the Helath Care REITs industry, Omega Healthcare Invts Inc. has a lower P/E ratio of <strong>30.43</strong>. Shareholders might be inclined to think that  the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1731431745_1.png" alt="Guage" /></p>

<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. </p>


Intraday Update

Price Over Earnings Overview: Omega Healthcare Invts

<p>During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.</p>
<p>Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.</p>
<p>Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.</p>
<h3 class="wp-block-heading"><strong>OUTFRONT Media Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUT#NYSE">OUT</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 6.65%</li>
<li><strong>Barrington Research </strong>analyst James Goss maintained an Outperform rating and raised the price target from $17 to $18 on Aug. 13. This analyst has an accuracy rate of 66%.</li>
<li><strong>TD Cowen</strong> analyst Lance Vitanza initiated coverage on the stock with a Hold rating and a price target of $16 on July 16. This analyst has an accuracy rate of 80%.</li>
<li><strong>Recent News:</strong> On Sept. 30, Scott Felenstein joined OUTFRONT Media as Senior Vice President of Brand Partnerships.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111224&amp;t=be2bearmibe3na1">latest OUT news</a> </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="817" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12050955/image-116.png" alt="" class="wp-image-642417" style="width:728px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12050955/image-116.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12050955/image-116-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12050955/image-116-768x692.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 6.47%</li>
<li><strong>RBC Capital </strong>analyst Michael Carroll maintained a Sector Perform rating and raised the price target from $39 to $43 on Nov. 11. This analyst has an accuracy rate of 61%.</li>
<li><strong>Wells Fargo </strong>analyst Connor Siversky assumed coverage on the stock with an Overweight rating and raised the price target from $40 to $43 on Oct. 1. This analyst has an accuracy rate of 66%.</li>
<li><strong>Recent News: </strong>On Oct. 30, Omega Healthcare Investors reported better-than-expected third-quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111224&amp;t=be2bearmibe3na1">latest OHI news</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="903" height="818" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051035/image-117.png" alt="" class="wp-image-642420" style="width:674px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051035/image-117.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051035/image-117-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051035/image-117-768x696.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>RLJ Lodging Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLJ#NYSE">RLJ</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield: </strong>6.12%</li>
<li><strong>Truist Securities </strong>analyst Gregory Miller maintained a Buy rating and cut the price target from $14 to $11 on Oct. 28. This analyst has an accuracy rate of 68%.</li>
<li><strong>Wolfe Research </strong>analyst Keegan Carl downgraded the stock from Outperform to Peer Perform on Sept. 26. This analyst has an accuracy rate of 67%.</li>
<li><strong>Recent News: </strong>On Nov. 6, RLJ Lodging posted better-than-expected quarterly sales.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111224&amp;t=be2bearmibe3na1">trend in RLJ stock</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="913" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051116/image-118.png" alt="" class="wp-image-642422" style="width:645px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051116/image-118.png 913w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051116/image-118-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051116/image-118-768x698.png 768w" sizes="(max-width: 913px) 100vw, 913px" /></a></figure></p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41877638/jim-cramer-tech-stock-go-to-160-recommends-buying-dominos-pizza">Jim Cramer: This Tech Stock Can &#8216;Go To 160,&#8217; Recommends Buying Domino&#8217;s Pizza</a></strong></li>
</ul>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>


Wall Street's Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields

<p>Across the recent three months, 6 analysts have shared their insights on Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.33, a high estimate of $45.00, and a low estimate of $39.00. Marking an increase of 11.98%, the current average surpasses the previous average price target of $37.80. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731348010_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Omega Healthcare Invts among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$43.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Kai Klose</td>
<td>Berenberg</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Juan Sanabria</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$39.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$39.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Omega Healthcare Invts. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Omega Healthcare Invts compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Omega Healthcare Invts's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OHI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Omega Healthcare Invts analyst ratings.</strong></a></p>
<h2>Discovering Omega Healthcare Invts: A Closer Look</h2>
<p>Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).</p>
<h3>Understanding the Numbers: Omega Healthcare Invts's Finances</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Omega Healthcare Invts displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>14.05%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>40.49%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Omega Healthcare Invts's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.82%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Omega Healthcare Invts's ROA excels beyond industry benchmarks, reaching <strong>1.21%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.15</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Omega Healthcare Invts: 6 Analysts Share Their Views

<p>RBC Capital  analyst Michael Carroll   maintains Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Sector Perform and raises the price target from $39 to $43.</p>


RBC Capital Maintains Sector Perform on Omega Healthcare Invts, Raises Price Target to $43

Press Releases

Omega Reports Second Quarter 2024 Results and Recent Developments

Omega Announces Third Quarter Earnings Release Date and Conference Call

Real Estate

Inspīr Carnegie Hill Wins 2024 Senior Living Development Award from The Americas Property Awards

Omega Announces Quarterly Dividend

Omega Reports Third Quarter 2024 Results and Recent Developments

Omega Announces Key Leadership Changes

Omega Announces Fourth Quarter Earnings Release Date and Conference Call

Omega Reports Fourth Quarter and Full Year 2024 Results

Inspīr Embassy Row Celebrates Grand Opening, Ushering in New Era of Luxury Senior Living in Washington D.C.

Comments

Omega Healthcare Invts

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga